AMMF’s Ballot for London Marathon 2016

As Silver Bond holders with the London Marathon, AMMF has one guaranteed place every five years, and our next place isn't due until 2020! However the marathon organisers now hold a 'Charity Ballot' for all those charities with no guaranteed places in the intervening years, and AMMF has been selected from this ballot to receive one place for the 2016 event. We know we have many loyal supporters who hav...

Read More

“Progress with targeted agents in cholangiocarcinoma – reality or myth?”

At the ESMO1 17th World Congress on Gastrointestinal Cancer held in Barcelona in July 2015, Professor Juan Valle, consultant and medical oncologist at The Christie, Manchester UK, and one of AMMF’s medical advisors, spoke about the progress being made in the understanding of cholangiocarcinoma, the studies being carried out to find target agents, and also genomic profiling, in the search for better and mo...

Read More

GWAS Cholangiocarcinoma Study

The Genome-wide Association Study (GWAS) for Cholangiocarcinoma Professor Simon Taylor-Robinson and Dr. Shahid Khan at Imperial College London are collaborating on the GWAS project with the Mayo clinic in the USA1, as one of their ongoing studies in cholangiocarcinoma. If you2 would be interested in donating blood and urine samples for analysis to the Imperial Hepatology & Gastroenterology BioBank...

Read More

The ABC-03 trial

As a result of the landmark ABC-02 study, the Cisplatin and Gemcitabine chemotherapy combination1 is recognised as the standard first-line treatment for those with inoperable biliary tract cancer (cholangiocarcinoma).  However, the search goes on for improvements to this regime. In the ABC-03 study, Cediranib (an anti angiogenic drug1) was added to the Gemcitabine / Cisplatin combination. Unfortu...

Read More

Interim Report from AMMF’s Research Fellow

AMMF has just received an interim report from the Institute of Hepatology in London on the cholangiocarcinoma research work being carried out there by our Research Fellow, Dr Gemma Choy. This work has involved investigating whether the MAPK signalling pathway allows intrahepatic cholangiocarcinoma cell proliferation.  We are very pleased to learn that the project is progressing well with results to ...

Read More

New Cancer Strategy for England published

The report, “Achieving world-class cancer outcomes: a strategy for England 2015-2020”, has just been published and has been widely welcomed by many in the cancer communities, including Cancer52. In January 2015, The Independent Cancer Taskforce1 was set up to develop a five-year strategy for cancer services.  The report is the result of responses to a Call for Evidence,  outputs from 30 workshops, ...

Read More

AMMF’s Summer Photo Comp is back!

“Give us your best shot #2” Throughout summer 2014 we loved seeing the imaginative photos that were submitted for AMMF's first photo competition. So "Give us you best shot" is back for 2015 - running from July to the end of September. We'd love to see your photos from wherever you happen to be spending your holiday, or just having a summer's day out - a picnic, walking, up a mountain, on the beach,...

Read More

Cholangiocarcinoma mortality higher than incidence?

The survival rate for cholangiocarcinoma is recognised to be extremely low, but how can mortality be higher than incidence? The statistics in the recently published NCIN1/Cancer522 Rare and Less Common Cancers report show not only that the incidence of cholangiocarcinoma is increasing year on year, but also that the mortality figures for the years 2012 and 2013 are higher than the incidence. This is also r...

Read More

AMMF and the Rare Cancer Report

by Helen Morement A year ago, I was invited to be part of the advisory board for a new collaborative project being undertaken by Public Health England's National Cancer Intelligence Network (NCIN1) and Cancer522. This aim of this project was to produce, for the first time, a list of as many of the rare and less common cancers as possible together with their correct ICD-10 codings3 and their incidence and m...

Read More

AMMF at the London Marathon 2015

What a fantastic day! The biggest London Marathon in history, and amongst the many thousands who crossed the finish line in The Mall, none were more important or had more good wishes going with them than AMMF’s three runners – Rachel, Gary and Gwilym. As 2015 was our Silver Bond year, we had one guaranteed place to offer. This went up for auction and the successful bidder was Rachel Munns, who wanted...

Read More